Trials / Unknown
UnknownNCT03510416
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .
Detailed description
Aptinib combined with TACE can be generated through embolization and angiogenesis by the dual target of vascular suppression.Efficacy and safety of apatinib combined with TACE in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | apatinib is a kind of Inhibitor of VEGFR-2 |
| RADIATION | TACE | Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE. |
Timeline
- Start date
- 2018-05-01
- Primary completion
- 2019-06-30
- Completion
- 2019-12-31
- First posted
- 2018-04-27
- Last updated
- 2018-04-27
Source: ClinicalTrials.gov record NCT03510416. Inclusion in this directory is not an endorsement.